Vertex Pharmaceuticals Reports 'Unprecedented' Results From Trial of VX-880 to Treat Type 1 Diabetes; Shares Nudge Higher

9:39AM ET 10/18/2021 MT Newswires
Vertex Pharmaceuticals (VRTX) said the first patient in a phase 1/2 clinical trial of VX-880 to treat type 1 diabetes achieved successful engraftment and demonstrated rapid and robust improvements in multiple measures.

The patient was treated with a single infusion of VX-880 at half the target dose in conjunction with immunosuppressive therapy.

The biotechnology company said it is the first demonstration of a patient with type 1 diabetes achieving robust restoration of islet cell function from such a cell therapy.

"These results from the first patient treated with VX-880 are unprecedented. What makes these results truly remarkable is that they were achieved with treatment at half the target dose," said Bastiano Sanna, chief of cell and genetic therapies. "While still early, these results support the continued progression of our VX-880 clinical studies."

Shares of Vertex Pharmaceuticals are up slightly in early trading.

Price: 181.92, Change: +0.14, Percent Change: +0.08